Biopharmaceutical Company
Appears in 1 story
Preparing commercial launch of Bysanti in H2 2026; raised full-year 2026 revenue guidance to $240–$290 million
The FDA approved Cobenfy for schizophrenia in September 2024—the first drug to treat the condition through muscarinic receptors rather than dopamine, a different approach than any approved in the previous 50 years. Bysanti (milsaperidone) followed in February 2026, cleared for both schizophrenia and bipolar I disorder. For the roughly 7 million Americans with these conditions, the treatment menu is wider than it was two years ago.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
